JBJI Journal of Bone and Joint Infection JBJI J. Bone Joint Infect. 2206-3552 Ivyspring Göttingen, Germany 10.7150/jbji.37262 Clinical Outcome of Antibiotic Suppressive Therapy in Patients with a Prosthetic Joint Infection after Hip Replacement Leijtens Borg 1 Weerwag Laura 1 Schreurs Berend Willem 1 Kullberg Bart-Jan 2 Rijnen Wim 1 Department of Orthopedic Surgery, Radboud University Medical Centre Nijmegen, the Netherlands Department of Internal Medicine/Infectious Diseases, Radboud University Medical Centre Nijmegen, the Netherlands 06 11 2019 4 6 268 276 Copyright: © 2019 Borg Leijtens et al. 2019 This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/ This article is available from https://jbji.copernicus.org/articles/4/268/2019/jbji-4-268-2019.html The full text article is available as a PDF file from https://jbji.copernicus.org/articles/4/268/2019/jbji-4-268-2019.pdf

<p class="p p-first" id="__p2"><strong>Introduction:</strong> In Specific cases, curative treatment of a prosthetic joint infection (PJI) cannot be accomplished due to the increased risk of major complications after prosthetic joint revision surgery. In these patients, antibiotic suppressive therapy (AST) is often used to control the infection.</p><p id="__p3"><strong>Aim:</strong> To describe the clinical outcome of patients with a PJI after hip replacement treated with AST.</p><p id="__p4"><strong>Methods:</strong> Patients in which AST for PJI was started between 2006 and 2013, were retrospectively included. Follow-up was continued until October 2018. AST has been defined as treatment with oral antibiotic therapy intended to suppress PJI. Treatment was considered successful in patients without reoperation for PJI or death related to PJI during follow-up.</p><p id="__p5"><strong>Results:</strong> Twenty-three patients were included. The most commonly used antibiotics were doxycycline (n=14) and cotrimoxazole (n=6). The mean duration of AST was 38 months (1-151 months). AST was considered successful in 13 patients (56.5%) after a median follow-up of 33 months. AST was least successful in PJI caused by S. <em>aureus</em> with 80% failures versus 33% in PJI caused by other microorganisms and in patients who had an antibiotic-free period before the start of AST with 83% failures. Two patients ended AST due to side effects.</p><p class="p p-last" id="__p6"><strong>Conclusion<em>:</em></strong> AST can be an alternative treatment in selected patients with a PJI after hip replacement. However, there is a persisting and considerable amount of failures, particularly in PJI caused by S. <em>aureus</em> and in patient with an antibiotic-free period before the start of AST.</p>

 References Parvizi J, Adeli B, Zmistowski B. et al. Management of periprosthetic joint infection: the current knowledge: AAOS exhibit selection. J Bone Joint Surg Am. 2012;94(14):e104.. doi: 10.2106/JBJS.K.01417. Zimmerli W, Ochsner PE. Management of infection associated with prosthetic joints. Infection. 2003;31(2):99–108. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351(16):1645–54. Osmon DR, Berbari EF, Berendt AR. et al. Infectious Diseases Society of America, Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:e1–e25. doi: 10.1093/cid/cis803. Aboltins C, Daffy J, Choong P. et al. Current concepts in the management of prosthetic joint infection. Intern Med J. 2014;44(9):834–40. doi: 10.1111/imj.12510. Goulet JA, Pellicci PM, Brause B. et al. Prolonged suppression of infection in total hip arthroplasty. J Arthroplasty. 1988;3(2):109–16. Tsukayama DT, Wicklund B, Gustilo RB. Suppressive antibiotic therapy in chronic prosthetic joint infections. Orthopedics. 1991;14(8):841–4. Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis. 1998;27(4):711–4. Rao N, Crossett LS, Sinha RK. et al. Long-term suppression of infection in total joint arthroplasty. Clin Orthop Relat Res. 2003;414:55–60. Prendki V, Zeller V, Passeron D. et al. Outcome of patients over 80 years of age on prolonged suppressive antibiotic therapy for at least 6 months for prosthetic joint infection. Int J Infect Dis. 2014;29:184–9. Siqueira MBP, Saleh A, Klika AK. et al. Chronic Suppression of Periprosthetic Joint Infections with Oral Antibiotics Increases Infection-Free Survivorship, J. Bone Joint Surg Am. 2015;97:1220–32. Wouthuyzen-Bakker M, Nijman JM, Kampinga GA. et al. Efficacy of Antibiotic Suppressive Therapy in Patients with a Prosthetic Joint Infection. J Bone Joint Infect. 2017;2:77–83. doi: 10.7150/jbji.17353. [PMC free article] Pradier M, Robineau O, Boucher A. et al. Suppressive antibiotic therapy with oral tetracyclines for prosthetic joint infections: a retrospective study of 78 patients. Infection. 2018;46(1):39–47. doi: 10.1007/s15010-017-1077-1. Parvizi J, Gehrke T. International Consensus Group on Periprosthetic Joint Infection, Definition of periprosthetic joint infection. J Arthroplasty. 2014;29(7):1331.. doi: 10.1016/j.arth.2014.03.009.